Category: Zacks Small Cap Research

1 2 3 4 36 20 / 358 POSTS
By David Bautz, PhDNASDAQ:BCLIREAD THE FULL BCLI RESEARCH REPORTBusiness UpdateHospital Exemption Application ApprovedOn March 13, 2019, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) held a conference call to announce that the Israeli Ministry of ...
By David Bautz, PhDNASDAQ:VKTXREAD THE FULL VKTX RESEARCH REPORTBusiness UpdateViking Therapeutics, Inc. (NASDAQ:VKTX) is a biopharmaceutical company developing treatments for metabolic and endocrine disorders. The company’s lead compounds include: 1 ...
By David Bautz, PhDNASDAQ:AGRXREAD THE FULL AGRX RESEARCH REPORTBusiness UpdateAgile Therapeutics, Inc. (NASDAQ:AGRX) is a women’s healthcare company focused on developing healthcare products to fulfill the unmet contraceptive needs of women. The com ...
By John Vandermosten, CFANASDAQ:LPCNREAD THE LATEST LPCN RESEARCH REPORTLipocine (NASDAQ:LPCN) announced topline results from its non-alcoholic steatohepatitis (NASH) liver fat study demonstrating relative liver fat reduction of 55% in patients with ...
By John Vandermosten, CFANASDAQ:ACHVREAD THE FULL ACHV RESEARCH REPORTINITIATING COVERAGEAchieve Life Sciences, Inc. (NASDAQ:ACHV) is developing cytisinicline, historically known as cytisine, for nicotine addiction. The drug is currently available ov ...
By John Vandermosten, CFANASDAQ:HTBXHeat Biologics, Inc. (NASDAQ:HTBX) has continued to progress in their HS-110 Durga trial, recently providing interim results at the ASCO-SITC Clinical Immuno-Oncology Symposium. The Phase II study is evaluating HS- ...
By Brian Marckx, CFAOTC:SMLRREAD THE FULL SMLR RESEARCH REPORTQ4 2018 Results: Revenue, Earnings & Cash Flow Continue to Climb. Cash Flow Forecast Implies $45/Share Fair Value…Semler (OTC:SMLR) reported financial results for the fourth quarter en ...
While using artificial intelligence and machine learning to optimize health care isn’t a novel concept, KenSci proclaims its mission is more broadly to fight death with data science. By collecting big data, analyzing variables and outcomes, and sugge ...
By David Bautz, PhDTSX:ATE.VREAD THE FULL ATE.V RESEARCH REPORTFinancial UpdateOn February 15, 2019, Antibe Therapeutics, Inc. (TSX:ATE.V) announced financial results for the third quarter of fiscal year 2019 ending Dec. 31, 2018. The company reporte ...
By David Bautz, PhDNASDAQ:MTFBREAD THE FULL MTFB RESEARCH REPORTBusiness UpdateCRL for IclaprimOn February 14, 2019, Motif Bio Plc (NASDAQ:MTFB) announced that the U.S. FDA issued a complete response letter (CRL) for the new drug application (NDA) fo ...
1 2 3 4 36 20 / 358 POSTS